Investors & Media

Welcome to the Investor Relations and Public Relations division of Medigene AG. This is where you will find current information on a variety of subjects, including Medigene AG shares, company news, financial reports and key figures.

Latest News

Medigene to present interim data analysis from Phase I/II DC-Vaccine trial at the EHA conference 2019


Medigene reports financial & business results for the first three months of 2019


bluebird presents preclinical data of first TCR candidate from Medigene collaboration. Start clinical development 2020


The Medigene Share

The Medigene share MDG1 (ISIN:DE000A1X3W00 ) is listed at the Frankfurt Stock Exchange since June 2000. 

show medigene share


21 - 23 May 2019

CIMT Annual Meeting

Mainz, Germany

22 May 2019

Annual General Meeting 2019

Munich, Germany

23 - 24 May 2019

The Immuno-Oncology 2019 World Congress

Barcelona, Spain

01 - 05 Jun 2019

ASCO - American Society of Clinical Oncology - Annual Meeting

Chicago, USA

02 - 05 Jun 2019

BIO International Convention

Booth 2201-3 German Pavillon

Philadelphia, USA

04 - 07 Jun 2019

Jefferies Global Healthcare Conference

New York, USA

07 Aug 2019

6-Months Report 2019

13 Nov 2019

9-Months Report 2019

Reports & Presentations


Company Presentation May 2019

DownLoad (2 MB)


Presentation on occasion of the 3 Months Report 2019

DownLoad (765 KB)


3 Months Report 2019

DownLoad (713 KB)

Annual General Meeting 2019

The Annual General Meeting of Medigene shareholders for fiscal year 2018 will be held in German language on Wednesday, 22 May 2019 at "Haus der Bayerischen Wirtschaft", Max-Joseph-Straße 5, 80333 Munich, Germany.

read more

Corporate Governance

Good corporate governance is the basis of our decision-making and monitoring processes. It stands for responsible and value-based leadership and control of the Company for long-term success, goal-oriented and efficient cooperation between the Executive Board and Supervisory Board, respect for the interests of our shareholders and employees, consistently transparent and responsible corporate decisions and an appropriate risk management system.

read more

press photos

Laboratory work

DownLoad (9 MB)

Laboratory work (6)

Cell culture work

DownLoad (4 MB)

Laboratory work (7)

Cell sorting

DownLoad (353 KB)

Contact person

Photo: Julia Hofmann

Julia Hofmann
Senior Director, Head of Public & Investor Relations
Telefon: +49-89-20 00 33-33 01
Fax: +49-89-20 00 33-29 20

Photo: Dr. Robert Mayer

Dr. Robert Mayer
Senior Manager Public & Investor Relations
Telefon: +49-89-20 00 33-33 01
Fax: +49-89-20 00 33-29 20